H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)

September 10, 2026 6:48 AM

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $344.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found